Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

  • Can-Fite BioPharma Ltd (NYSE:CANFannounced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.
  • The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically equivalent efficacy responses. 
  • At week 16, patients receiving Piclidenoson 3mg demonstrated statistically significant improvement compared with placebo, as measured by the Psoriasis Area and Severity Index (PASI) 75 response - Piclidenoson 3mg: 9.7% vs. placebo: 2.6%. 
  • Related: Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study.
  • Secondary endpoint parameters at week 32 comparing Piclidenoson to the active control drug, Amgen Inc's (NASDAQ:AMGN) Otezla (apremilast), revealed inferiority related to PASI 75 (17% vs. 26.2%) and PASI 50 (34.1% vs. 49.5%).
  • But revealed the superiority of Piclidenoson compared to Otezla in the Psoriasis Disability Index (PDI) (20.5% vs. 10.3%).
  • Piclidenoson showed a favorable safety profile.
  • Price Action: CANF shares are up 33.8% at $1.19 during the premarket session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.